person · Reporting owner
Flagship Ventures Opportunities Fund I, L.P.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | 10% owner | October 13, 2022 | October 17, 2022 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | 10% owner | May 27, 2022 | June 01, 2022 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director · 10% owner | January 13, 2026 | January 15, 2026 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | 10% owner | February 08, 2021 | February 10, 2021 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | 10% owner | March 19, 2021 | March 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date October 13, 2022 · Filed October 17, 2022
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 14,101,638 |
Last balance in matching sequence
After 2022-10-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-10-13 · Purchase · Acquired 2,743,902 · Balance 11,344,305 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Row 2 · 2022-10-13 · Purchase · Acquired 2,757,333 · Balance 14,101,638 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities I, L.P. | 6,299,611 |
Last balance in matching sequence
After 2022-10-13 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2022-10-13 · Purchase · Acquired 914,634 · Balance 5,380,500 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Row 4 · 2022-10-13 · Purchase · Acquired 919,111 · Balance 6,299,611 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy FPA, L.P. | 3,048,780 |
Reported balance
After 2022-10-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-10-13 · Purchase · Acquired 3,048,780 · Balance 3,048,780 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 2,004,657 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,004,657 F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV, LLC | 2,035,830 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,035,830 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund 2007, L.P. | 1,761,029 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,761,029 F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Evelo Biosciences, Inc.
Report date May 27, 2022 · Filed June 01, 2022
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 7,590,873 |
Reported balance
After 2022-05-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-05-27 · Purchase · Acquired 4,383,561 · Balance 7,590,873 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 1,887,419 |
Reported balance
After 2022-05-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-05-27 · Purchase · Acquired 1,095,890 · Balance 1,887,419 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities Fund I, L.P. | 5,495,324 |
Reported balance
After 2022-05-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-05-27 · Purchase · Acquired 1,369,863 · Balance 5,495,324 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 8,219,791 |
Reported balance
After 2022-05-27 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-05-27 · Purchase · Acquired 6,849,315 · Balance 8,219,791 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F5: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 13,698,630 |
Reported balance
After 2022-05-27 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-05-27 · Purchase · Acquired 13,698,630 · Balance 13,698,630 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F6: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 684,372 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 684,372 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V LLC | 2,645,637 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,645,637 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 4,201,284 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 4,201,284 F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 1,609,871 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 1,609,871 F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Side Fund, L.P. | 795,950 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 795,950 F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Disruptive Innovation Fund, L.P. | 3,598,177 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 3,598,177 F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Foghorn Therapeutics Inc.
Report date January 13, 2026 · Filed January 15, 2026
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2046-01-13 | IndirectBy Flagship Pioneering Fund VII, L.P. | 2,235,468 |
Reported balance
After 2026-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-13 · Grant · Acquired 2,235,468 · Balance 2,235,468 F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 1 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.42 · Expires 2027-06-30 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 2 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.13 · Expires 2030-12-31 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.
F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.
Kaleido Biosciences, Inc.
Report date February 08, 2021 · Filed February 10, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,685,444 |
Reported balance
After 2021-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-08 · Purchase · Acquired 71,666 · Balance 1,685,444 F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,982,639 |
Reported balance
After 2021-02-08 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 2,982,639 F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 738,333 |
Reported balance
After 2021-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 738,333 F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering. F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 42,865 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,865 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,500,000 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,500,000 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,560,096 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,560,096 F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 639,360 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 639,360 F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,560,523 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,560,523 F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 216,451 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 216,451 F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,649,999 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,649,999 F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.
F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Rubius Therapeutics, Inc.
Report date March 19, 2021 · Filed March 23, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,393,593 |
Reported balance
After 2021-03-19 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 15,393,593 F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,859,414 |
Reported balance
After 2021-03-19 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 5,859,414 F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering. F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,633,703 |
Reported balance
After 2021-03-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 2,633,703 F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering. F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,000,000 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,000,000 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,830,402 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,830,402 F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,789,414 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,789,414 F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP.
F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering.
F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering.
F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 2 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $20.13 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 3 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2030-12-31 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 1 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $13.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 2 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2027-06-30 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantPre-Funded Warrants to purchase Common Stock · Derivative | 2,235,468 | $6.71 Strike: $0.00 | $14,999,766.73 |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 1 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 2,235,468 Underlying: Common Stock · 2,235,468 shares Expires 2046-01-13 F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 3,048,780 | $1.64 | $4,999,999.20 |
DisclosureSEC source: 0000899243-22-033703 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By FPA, L.P. Disclosed balance after: 3,048,780 F1 · kind: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F5 · ownership.nature: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 919,111 | $1.64 | $1,507,342.04 |
DisclosureSEC source: 0000899243-22-033703 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Opportunities I, L.P. Disclosed balance after: 6,299,611 F3 · kind: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 914,634 | $1.64 | $1,499,999.76 |
DisclosureSEC source: 0000899243-22-033703 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Opportunities I, L.P. Disclosed balance after: 5,380,500 F1 · kind: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 2,757,333 | $1.64 | $4,522,026.12 |
DisclosureSEC source: 0000899243-22-033703 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 14,101,638 F3 · kind: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 2,743,902 | $1.64 | $4,499,999.28 |
DisclosureSEC source: 0000899243-22-033703 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 11,344,305 F1 · kind: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 13,698,630 | $1.46 | $19,999,999.80 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 13,698,630 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F6 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 6,849,315 | $1.46 | $9,999,999.90 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 8,219,791 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F5 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,369,863 | $1.46 | $1,999,999.98 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Opportunities Fund I, L.P. Disclosed balance after: 5,495,324 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,095,890 | $1.46 | $1,599,999.40 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 1,887,419 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 19:00 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 4,383,561 | $1.46 | $6,399,999.06 |
DisclosureSEC source: 0000899243-22-020533 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 7,590,873 F1 · kind: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 12:30 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,579,843 | $1.91 | $3,017,500.13 |
DisclosureSEC source: 0000899243-22-011535 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Opportunities I, L.P. Disclosed balance after: 4,465,866 F1 · kind: On March 16, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") and Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 3,791,623 shares, 947,905 shares and 1,579,843 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a pirce of $1.91 per share. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 12:30 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 947,905 | $1.91 | $1,810,498.55 |
DisclosureSEC source: 0000899243-22-011535 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV-Rx, L.P. Disclosed balance after: 2,004,657 F1 · kind: On March 16, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") and Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 3,791,623 shares, 947,905 shares and 1,579,843 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a pirce of $1.91 per share. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 12:30 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 3,791,623 | $1.91 | $7,241,999.93 |
DisclosureSEC source: 0000899243-22-011535 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 8,600,403 F1 · kind: On March 16, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") and Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 3,791,623 shares, 947,905 shares and 1,579,843 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a pirce of $1.91 per share. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 17:30 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 70,000 | $29.00 | $2,030,000.00 |
DisclosureSEC source: 0000899243-21-013179 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,633,703 F5 · shares: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering. F6 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 17:30 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 70,000 | $29.00 | $2,030,000.00 |
DisclosureSEC source: 0000899243-21-013179 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,859,414 F3 · shares: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering. F4 · ownership.nature: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 17:30 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | PurchaseCommon Stock | 70,000 | $29.00 | $2,030,000.00 |
DisclosureSEC source: 0000899243-21-013179 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 15,393,593 F1 · shares: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:30 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 71,667 | $11.50 | $824,170.50 |
DisclosureSEC source: 0000899243-21-005713 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 738,333 F5 · shares: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering. F6 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:30 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 71,667 | $11.50 | $824,170.50 |
DisclosureSEC source: 0000899243-21-005713 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,982,639 F3 · shares: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:30 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 71,666 | $11.50 | $824,159.00 |
DisclosureSEC source: 0000899243-21-005713 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,685,444 F1 · shares: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 46,429 | $15.00 | $696,435.00 |
DisclosureSEC source: 0000899243-21-004962 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,125,461 F7 · shares: On February 2, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 46,429 shares pursuant to the Offering. F8 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 37,143 | $15.00 | $557,145.00 |
DisclosureSEC source: 0000899243-21-004962 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,370,476 F5 · shares: On February 2, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 37,143 shares pursuant to the Offering. F6 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 9,285 | $15.00 | $139,275.00 |
DisclosureSEC source: 0000899243-21-004962 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 791,529 F3 · shares: On February 2, 2021, Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") acquired 9,285 shares pursuant to the offering. F4 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 17:56 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 37,143 | $15.00 | $557,145.00 |
DisclosureSEC source: 0000899243-21-004962 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,207,312 F1 · shares: On February 2, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 37,143 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · derivative · entry 13 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,801,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F4 · ownership.nature: Shares held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is sole director of Flagship Pioneering. Each of Noubar B. Afeyan Ph.D., Flagship Pioneering, and Opportunities Fund II GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionSeries B Convertible Preferred Stock · Derivative | 2,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · derivative · entry 12 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,441,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F3 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities Fund I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Opportunities Fund I GP") is the general partner of Flagship Opportunities Fund I. Noubar B. Afeyan Ph.D. serves as the sole manager of Opportunities Fund I GP. Each of Opportunities Fund I GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,336,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · derivative · entry 11 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 722,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 8,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · derivative · entry 10 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,504,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 7,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · derivative · entry 9 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,054,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F1 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchaseCommon Stock | 50,000 | $16.00 | $800,000.00 |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 8 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,851,801 F4 · ownership.nature: Shares held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is sole director of Flagship Pioneering. Each of Noubar B. Afeyan Ph.D., Flagship Pioneering, and Opportunities Fund II GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionCommon Stock | 1,801,801 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 7 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,801,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F4 · ownership.nature: Shares held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is sole director of Flagship Pioneering. Each of Noubar B. Afeyan Ph.D., Flagship Pioneering, and Opportunities Fund II GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchaseCommon Stock | 50,000 | $16.00 | $800,000.00 |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 6 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,491,441 F3 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities Fund I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Opportunities Fund I GP") is the general partner of Flagship Opportunities Fund I. Noubar B. Afeyan Ph.D. serves as the sole manager of Opportunities Fund I GP. Each of Opportunities Fund I GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionCommon Stock | 1,441,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,441,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F3 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities Fund I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Opportunities Fund I GP") is the general partner of Flagship Opportunities Fund I. Noubar B. Afeyan Ph.D. serves as the sole manager of Opportunities Fund I GP. Each of Opportunities Fund I GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | PurchaseCommon Stock | 50,000 | $16.00 | $800,000.00 |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,330,878 F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionCommon Stock | 722,320 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,280,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionCommon Stock | 4,504,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,558,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 29, 2020 16:58 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | ConversionCommon Stock | 4,054,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029693 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,054,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into the number of shares of the Registrant's common stock shown in Table II, column 7 and has no expiration date. The Preferred Stock automatically converted into common stock upon the closing of the Registrant's initial public offering, which occurred on October 27, 2020. F2 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan Ph.D. serves as the sole manager of Fund V GP. Each of Fund V GP and Noubar B. Afeyan Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:24 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,666,667 | $3.75 | $6,250,001.25 |
DisclosureSEC source: 0000899243-20-018150 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,079,032 F7 · shares: On June 29, 2020, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 1,666,667 shares pursuant to the Offering. F8 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:24 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,333,333 | $3.75 | $4,999,998.75 |
DisclosureSEC source: 0000899243-20-018150 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,333,333 F5 · shares: On June 29, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 1,333,333 shares pursuant to the Offering. F6 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:24 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 333,333 | $3.75 | $1,249,998.75 |
DisclosureSEC source: 0000899243-20-018150 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 782,244 F3 · shares: On June 29, 2020, Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") acquired 333,333 shares pursuant to the offering. F4 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:24 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,333,333 | $3.75 | $4,999,998.75 |
DisclosureSEC source: 0000899243-20-018150 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,170,169 F1 · shares: On June 29, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 1,333,333 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. ("Flagship Pioneering") and as a manager of Flagship Fund IV GP. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:46 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 666,666 | $7.50 | $4,999,995.00 |
DisclosureSEC source: 0000899243-20-015630 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 666,666 F5 · shares: On June 4, 2020, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 666,666 shares pursuant to the Offering. F6 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:46 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 666,667 | $7.50 | $5,000,002.50 |
DisclosureSEC source: 0000899243-20-015630 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,910,972 F3 · shares: On June 4, 2020, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 666,667 shares pursuant to the Offering. F4 · ownership.nature: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:46 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 666,667 | $7.50 | $5,000,002.50 |
DisclosureSEC source: 0000899243-20-015630 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,613,778 F1 · shares: On June 4, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 666,667 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. ("Flagship Pioneering") and as a manager of Flagship Fund IV GP. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,900,000 | $4.75 | $9,025,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,886,023 F3 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 380,000 | $4.75 | $1,805,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,056,752 F2 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:15 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 1,520,000 | $4.75 | $7,220,000.00 |
DisclosureSEC source: 0000899243-20-013708 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,808,780 F1 · ownership.nature: Shares held by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 895,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 25 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 486,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.